Diagnostic marker for ovarian cancer
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to methods of detecting, monitoring the efficacy of treatment of, and assessing the severity of ovarian cancer, by assessing the concentration of haptoglobin-1 precursor in a sample of biological fluid. The invention also relates to a kit comprising an antibody or nucleic acid probe specific for haptoglobin-1 precursor for use in the diagnosis of ovarian cancer, monitoring the efficacy of treatment of ovarian cancer, or assessing the severity of ovarian cancer.
-
Citations
39 Claims
-
1-16. -16. (canceled)
-
17. A method of detecting ovarian cancer comprising;
determining the concentration of haptoglobin-1 precursor in a sample of a biological fluid from a subject suspected to be suffering from ovarian cancer, wherein an increased concentration of haptoglobin-I precursor compared to the concentration of haptoglobin-1 precursor in a control sample is an indication of the presence of said cancer. - View Dependent Claims (18, 19, 20, 21, 22, 23)
-
24. The method of monitoring the efficacy of treatment of ovarian cancer, comprising;
determining the concentration of haptoglobin-1 precursor in a sample of a biological fluid from a subject suspected to be suffering from ovarian cancer, wherein a decrease in haptoglobin-1 precursor level compared to the level before treatment is an indication of efficacy of said treatment. - View Dependent Claims (25, 26, 27, 28, 29, 30)
-
31. A method of assessing the severity of ovarian cancer comprising;
determining the concentration of haptoglobin-1 precursor in a biological fluid of a subject diagnosed with, or suspected to be suffering from, ovarian cancer, wherein an increased concentration of haptoglobin-1 precursor compared to the concentration of haptoglobin-1 precursor in a control sample is an indication of the severity of said cancer. - View Dependent Claims (32, 33, 34, 35, 36, 37)
-
38. A kit comprising;
-
a probe specific for haptoglobin-1 precursor selected from the group consisting of an antibody and nucleic acid; and
instructions. - View Dependent Claims (39)
-
Specification